Drugs / Testofen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05232279 | Apr 2022 → Jun 2026 overdue | erectile dysfunction | RDC Clinical Pty Ltd | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05795816 Comparator | Oct 2023 → Jan 2025 | long COVID-19 | RDC Clinical Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Testofen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05795816 ↗ |
| Route | Oral | “Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.” NCT05232279 ↗ |